RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.
Overall survival (OS) is currently the primary
criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant
medical oncologist at the National University Hospital, Singapore, details the
crucial role played by tumour response in evaluating treatment efficacy, with a
focus on the multiple kinase inhibitor lenvatinib in the treatment of
hepatocellular carcinoma (HCC).
All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
In obese patients without gallstones, a 6-month treatment course of ursodeoxycholic acid (UDCA) following bariatric surgery may reduce their likelihood of developing symptomatic gallstones, according to findings of the UPGRADE trial from The Netherlands presented at DDW 2021.
Apart from reducing bleeding risk in individuals with advanced oesophageal cancer (ESCA) who had self-expanding metal stent (SEMS) insertion to improve dysphagia, concurrent palliative radiotherapy (RT) does not reduce recurrent dysphagia nor does it improve overall survival (OS), findings from the phase III ROCS* study have shown.